The DOI matches its Crossref record; 47 of the 48 references it cites were found in a registry or an index.
The First Frontier: Digital Biomarkers for Neurodegenerative Disorders
Open accessAbstract
Current measures of neurodegenerative diseases are highly subjective and based on episodic visits. Consequently, drug development decisions rely on sparse, subjective data, which have led to the conduct of large-scale phase 3 trials of drugs that are likely not effective. Such failures are costly, deter future investment, and hinder the development of treatments. Given the lack of reliable physiological biomarkers, digital biomarkers may help to address current shortcomings. Objective, high-frequency data can guide critical decision-making in therapeutic development and allow for a more efficient evaluation of therapies of increasingly common disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The promise of digital biomarkers to create a paradigm shift in biomedical research and clinical treatment monitoring is evident.3”
From Evaluation of smartphone‐based testing to generate exploratory outcome measures in a phase 1 Parkinson's disease clinical trial (2018) · cites this paper as [3]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Goetz, C. G., Tilley, B. C., Shaftman, S. R., Stebbins, G. T., Fahn, S., Martinez‐Martin, P., Poewe, W., Sampaio, C., Stern, M. B., Dodel, R., et al. (2008) · Movement Disorders · doi:10.1002/mds.22340 · Cited by 7,536
A new rating scale for Alzheimer's disease
(1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.11.1356 · Cited by 4,175
Adams, J., Dinesh, K., Xiong, M., Tarolli, C. G., Sharma, S., Sheth, N., Aranyosi, A. J., Zhu, W. Y., Goldenthal, S. B., Biglan, K., et al. (2017) · Digital Biomarkers · doi:10.1159/000479018 · Cited by 3,190
Self-citationThe State of US Health, 1990-2010: Burden of Diseases, Injuries, and Risk Factors
Murray, C. J. L. (2013) · JAMA · doi:10.1001/jama.2013.13805 · Cited by 2,438
Effects of Coenzyme Q10 in Early Parkinson Disease: Evidence of Slowing of the Functional Decline
Shults, C. W. (2002) · Archives of Neurology · doi:10.1001/archneur.59.10.1541 · Cited by 984
Estimating The Cost Of New Drug Development: Is It Really $802 Million?
Adams, C., & Brantner, V. V. (2006) · Health Affairs · doi:10.1377/hlthaff.25.2.420 · Cited by 917
Technology in Parkinson’s disease: challenges and opportunities
Espay, A. J., Bonato, P., Nahab, F. B., Maetzler, W., Dean, J. M., Klucken, J., Eskofier, B. M., Merola, A., Horak, F., Lang, A. E., et al. (2016) · Movement Disorders · doi:10.1002/mds.26642 · Cited by 654
Self-citationIsosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction
Redfield, M. M., Anstrom, K. J., Levine, J. A., Koepp, G. A., Borlaug, B. A., Chen, H. H., LeWinter, M. M., Joseph, S. M., Shah, S. J., Semigran, M. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510774 · Cited by 556
The NINDS NET-PD Investigators (2006) · Neurology · doi:10.1212/01.wnl.0000201252.57661.e1 · Cited by 453
Research works printed but not linked: 1
- 10.1001/jama.2015.120 · DOI · Paper page
Cited by
Sorted by citations
Digital biomarkers for Alzheimer’s disease: the mobile/wearable devices opportunity
Kourtis, L. C., Regele, O. B., Wright, J. M., & Jones, G. B. (2019) · npj Digital Medicine · doi:10.1038/s41746-019-0084-2 · Cited by 476
Digital Twins for Multiple Sclerosis
Voigt, I., Inojosa, H., Dillenseger, A., Haase, R., Akgün, K., & Ziemssen, T. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.669811 · Cited by 294
Lipsmeier, F., Taylor, K. I., Kilchenmann, T., Wolf, D., Scotland, A., Schjodt‐Eriksen, J., Cheng, W., Fernandez‐Garcia, I., Siebourg‐Polster, J., Jin, L., et al. (2018) · Movement Disorders · doi:10.1002/mds.27376 · Cited by 266
“The promise of digital biomarkers to create a paradigm shift in biomedical research and clinical treatment monitoring is evident.(3) Our study demonstrates that digital biomarkers have now become feasible.”
BackgroundTeleneurology and mobile technologies: the future of neurological care
Dorsey, E. R., Glidden, A. M., Holloway, M. R., Birbeck, G. L., & Schwamm, L. H. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2018.31 · Cited by 258
Self-citationPowers, R., Etezadi‐Amoli, M., Arnold, E. M., Kianian, S., Mance, I., Gibiansky, M. L., Trietsch, D., Alvarado, A. S., Kretlow, J. D., Herrington, T. M., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abd7865 · Cited by 204
Metadata
- Authors
- Dorsey, E. R., Papapetropoulos, S., Xiong, M., & Kieburtz, K.
- Affiliations
- University of Rochester Medicine (US)
- Venue
- Digital Biomarkers
- Publisher
- S. Karger AG
- Published
- 2017-07-04
- Volume
- 1
- Issue
- 1
- Pages
- 6-13
- ISSN
- 2504-110X (ISSN-L)
- PMC
- PMC7015357
- OpenAlex
- W2732150368
- Cited by
- 162
- References
- 48
- Citations by year
- 2026: 18 · 2025: 30 · 2024: 18 · 2023: 19 · 2022: 28 · 2021: 18 · 2020: 12 · 2019: 12 · 2018: 6 · 2017: 1
- FWCI
- 1.29
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Digital Biomarkers (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Neurological Disorders and Stroke (P20NS092529)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Mental Health Research Topics
- Social Sciences › Psychology › Applied Psychology › Digital Mental Health Interventions
- Keywords
- neurodegenerative diseases, disease progression monitoring, drug development, objective outcome measures, treatment evaluation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
